GSK, Theravance announce FDA approval of COPD therapy
The inhaled long-term, once-daily maintenance treatment is also indicated for the reduction of exacerbations in COPD patients with possible future episodes of exacerbations. Breo Ellipta comprises inhaled corticosteroid
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.